Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
CME ACTIVITY - Research

Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis1

Katarina Ogrinc2, Sergio A. Hernández2, Miša Korva, Petra Bogovič, Tereza Rojko, Lara Lusa, Geena Chiumento, Franc Strle3, and Klemen Strle3Comments to Author 
Author affiliations: University Medical Center Ljubljana, Ljubljana, Slovenia (K. Ogrinc, P. Bogovič, T. Rojko, F. Strle); New York State Department of Health, Albany, New York, USA (S.A. Hernández, K. Strle); University of Ljubljana, Ljubljana (M. Korva, L. Lusa); Massachusetts Department of Public Health, Boston, Massachusetts, USA (G. Chiumento)

Main Article

Table 2

Immune mediators in cerebrospinal fluid and serum in 61 confirmed patients with Lyme neuroborreliosis, Ljubljana, Slovenia, 2006–2013*

Cytokine or chemokine CSF, pg/mL Serum, pg/mL p value†
Innate
IL-8 39 (8–289) 8 (0–473) <0.0001
IL-10 0.3 (0–54) 0.3 (0–28) 0.0001
TNF 5 (1–54) 7 (0–170) 0.3
IFN-α 88 (0–406) 22 (0–205) <0.0001
CCL2 343 (71–10,000) 213 (7–516) <0.0001
CCL3 5 (0.3–16) 1 (0.3–227) 0.07
CCL4
 5 (0.3–139)
 20 (0.3–221)
 <0.0001
T-cell adaptive
IFNγ 2 (0–77) 1 (0–25) 0.3
CXCL9 347 (4–6833) 170 (2–3,508) 0.02
CXCL10 4,139 (156–46,025) 143 (3–932) <0.0001
IL-17 3 (0–8) 2 (0–25) 0.02
IL-23 2 (2–33) 2 (2–4,949) 0.01
GM-CSF 5 (0–22) 3 (0–22) <0.0001
CCL19 84 (19–768) 28 (2–143) <0.0001
CCL21
 17 (17–241)
 17 (17–541)
 0.7
B-cell adaptive
CXCL12 1,541 (89–5,518) 820 (89–4184) <0.0001
CXCL13 352 (1–76,869) 9 (1–66) <0.0001

*Values are median (range). CCL, CC motif chemokine ligand; CSF, cerebrospinal fluid; CXCL, CXC motif chemokine ligand; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor. †Statistical analyses were performed using Mann-Whitney non-parametric rank sum test. Bold type indicates statistically significant p values after Benjamini-Hochberg correction for multiple comparisons (false discovery rate FDR = 0.05).

Main Article

1Part of the research reported here was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (online), July 9–12, 2021.

2These first authors contributed equally to this article.

3These senior authors contributed equally to this article.

Page created: February 22, 2022
Page updated: March 22, 2022
Page reviewed: March 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external